The initial public offer (IPO) of Star Imaging and Path Lab received bids for 1,80,94,000 shares as against 35,88,000 shares on offer. The issue was subscribed 5.04 times.
Qualified Institutional Buyers (QIBs) bid for 1,11,88,000 shares, Non-Institutional Investors (NIIs) for 33,58,000 shares, while individual investors (IND category bidding for 2 lots) placed bids for 35,32,000 shares.
The issue opened for bidding on 8 August 2025 and it closed on 12 August 2025. The price of the IPO is fixed between Rs 135-142 per share. The equity shares will list on BSE’s SME platform.
The IPO comprised a fresh issue of 39,20,000 equity shares and an offer for sale (OFS) of 9,72,000 shares. The promoter shareholding in the company will dilute to 71.92% post-IPO from 100% pre-IPO.
The company intends to utilize the net proceeds for repayment/prepayment of certain borrowings, funding the capital expenditure towards installation of medical equipment in running facilities, to meet working capital requirements, and for general corporate purposes.
Ahead of the IPO, Star Imaging and Path Lab, on 7 August 2025, raised Rs 18.51 crore from anchor investors. The board allotted 13.04 lakh shares at Rs 142 each to 11 anchor investors.
Star Imaging and Path Lab operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, cardiology, and neurology services in the Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G model) regions of India. It offers a comprehensive range of diagnostic imaging services and clinical laboratory tests. As of March 31st, 2025, the company has 211 full-time employees, including executive directors.
The company recorded revenue from operations of Rs 83.50 crore and a net profit of Rs 15.95 crore for the period ended 31 March 2025.